These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31447062)

  • 1. PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
    Krawczyk P; Grenda A; Wojas-Krawczyk K; Nicoś M; Kucharczyk T; Jarosz B; Reszka K; Pankowski J; Krukowska K; Bożyk A; Szumiło J; Sawicki M; Trojanowski T; Milanowski J
    Cancer Genet; 2019 Sep; 237():10-18. PubMed ID: 31447062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
    Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
    J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.
    Xu H; Lin G; Huang C; Zhu W; Miao Q; Fan X; Wu B; Zheng X; Lin X; Jiang K; Hu D; Li C
    Sci Rep; 2017 Dec; 7(1):16956. PubMed ID: 29209070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
    Kim GJ; Lee JH; Park WJ; Lee HW; Hwang IS; Lee DH
    Ann Clin Lab Sci; 2019 May; 49(3):317-323. PubMed ID: 31308030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma.
    Grenda A; Krawczyk P; Kucharczyk T; Błach J; Reszka K; Chmielewska I; Buczkowski J; Kieszko R; Siwiec J; Kubiatowski T; Bożyk A; Krukowska K; Jarosz B; Paśnik I; Pankowski J; Świniuch D; Stencel K; Gil M; Lew K; Ramlau R; Szczęsna A; Fidler S; Sieracki A; Każarnowicz A; Serwatowski P; Grodzki T; Milanowski J
    Oncol Lett; 2021 Jun; 21(6):449. PubMed ID: 33868487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
    Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S
    Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC.
    Polcaro G; Liguori L; Manzo V; Chianese A; Donadio G; Caputo A; Scognamiglio G; Dell'Annunziata F; Langella M; Corbi G; Ottaiano A; Cascella M; Perri F; De Marco M; Col JD; Nassa G; Giurato G; Zeppa P; Filippelli A; Franci G; Piaz FD; Conti V; Pepe S; Sabbatino F
    Mol Cancer; 2024 Mar; 23(1):63. PubMed ID: 38528526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.
    Shi X; Wu S; Sun J; Liu Y; Zeng X; Liang Z
    Sci Rep; 2017 Apr; 7():46209. PubMed ID: 28387300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
    Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
    PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype.
    Aujla S; Aloe C; Vannitamby A; Hendry S; Rangamuwa K; Wang H; Vlahos R; Selemidis S; Leong T; Steinfort D; Bozinovski S
    J Thorac Oncol; 2022 May; 17(5):675-687. PubMed ID: 35124252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
    Tseng JS; Yang TY; Wu CY; Ku WH; Chen KC; Hsu KH; Huang YH; Su KY; Yu SL; Chang GC
    J Immunother; 2018; 41(6):292-299. PubMed ID: 29683890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
    Song P; Guo L; Li W; Zhang F; Ying J; Gao S
    J Immunother; 2019 Jan; 42(1):23-28. PubMed ID: 30407231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Kim EY; Kim A; Kim SK; Chang YS
    Lung Cancer; 2017 Aug; 110():63-67. PubMed ID: 28676221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.